(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 November 2017 (23.11.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/199072 A1

(51) International Patent Classification:
A61K 31/13 (2006.01) *A61P 25/28* (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:
PCT/IB2016/054674

(22) International Filing Date:
03 August 2016 (03.08.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
201641017203 18 May 2016 (18.05.2016) IN

(71) Applicant: **SUVEN LIFE SCIENCES LIMITED** [IN/IN]; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN).

(72) Inventors: **NIROGI, Ramakrishna**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **SHINDE, Anil Karbhari**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **JAYARAJAN, Pradeep**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **BHYRAPUNENI, Gopinadh**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **KAMBHAMPATI, Ramasastri**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **JASTI, Venkateswarlu**; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN).


(74) Agent: **BHASIN, Gayatri** et al.; Central Square, Suite - 328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu Rao (off Rani Jhansi Road), Delhi 110 006 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST

Figure 1a



Data represents Mean ± SEM of discriminative index. *$p<0.05$ Vs vehicle (Kruskal-Wallis followed by Dunn's Multiple Comparison Test) N=8-11

(57) Abstract: The present invention relates to pure 5-HT_6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.

WO 2017/199072 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*